Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and CyclophosphamidePaola Papaldo, F. Calabresi, G. Ferretti et al.|Journal of Clinical Oncology|2005Cited by 96
Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and CyclophosphamidePaola Papaldo, Paolo Marolla, Massimo Lopez et al.|Journal of Clinical Oncology|2003Cited by 76
Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?Paola Papaldo, Francesco Cognetti, G. Ferretti et al.|Journal of Clinical Oncology|2006Cited by 42
Altered Expression of FAS System Is Related to Adverse Clinical Outcome in Stage I-II Breast Cancer Patients Treated with Adjuvant Anthracycline-Based ChemotherapyClaudio Botti, Marcella Mottolese, Simonetta Buglioni et al.|Clinical Cancer Research|2004Cited by 40
Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activityNadia Zaffaroni, Maria Grazia Daidone, Marcella Mottolese et al.|The Journal of Pathology|2002Cited by 35